Colorectal Cancer – Geographic Focus: China – Colorectal Cancer – China In-Depth (China)
Colorectal cancer is a major public health concern in China and is expected to become the second-most-common cancer in the country by 2031. The treatment of metastatic colorectal cancer is dominated by chemotherapy regimens prescribed in combination with VEGF inhibitors and EGFR inhibitors. Unlike in the major markets, only a few targeted therapies—including Roche’s Avastin, Merck’s Erbitux, and Bayer’s Stivarga, Chi-Med’s Elunate—are available in China for the treatment of colorectal cancer. However, the recent launch of PD-(L)1 inhibitors—Merck’s Keytruda and BeiGene’s tislelizumab—and the anticipated launch and uptake of more targeted therapies—Mirati’s adagrasib, Pfizer’s encorafenib, Merck’s favezelimab/pembrolizumab FDC, BMS’s relatlimab/nivolumab FDC —during the 2021-2031 period will lead to significant growth of China’s colorectal cancer therapy market. Nonetheless, the need for additional effective, targeted therapies for colorectal cancer will remain high, representing a lucrative opportunity for drug developers. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter the market over the coming years.
- How large is China’s drug-treatable colorectal cancer population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s colorectal cancer market and why? What are interviewed experts’ insights into current treatment options?
- What are the market access considerations for key therapies in the colorectal cancer pipeline in China? What sales could they secure in colorectal cancer? What are interviewed experts’ opinions of these therapies?
- What are the key drivers of and constraints in China’s colorectal cancer therapy market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Release date
December 2022
Geography
China
Primary research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 75 medical oncologists.
Epidemiology
Diagnosed incidence of colorectal cancer in urban versus rural China; clinically relevant and commercially relevant drug-treatable populations.
FORECAST
10-year, annualized, drug-level sales, and patient share of key colorectal cancer therapies through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
EMERGING THERAPIES
Phase III/PR: 10+ drugs; Phase II: 20+ drugs; coverage of Phase I products.
Table of contents
Chakradhar Reddy, B.Tech., Healthcare Research & Data Analyst, China-In-Depth. Mr. Reddy has several years’ experience in competitive intelligence and commercial analytics in the healthcare domain. Prior to joining Clarivate, he was an analyst in oncology and thought leadership at IQVIA. He holds a bachelor’s degree in genetic engineering from PRIST University in Thanjavur, India.
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. His areas of interest are cancer and psychiatric epidemiology. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.